#USA #New York #Class Action #Gross Law Firm #Iovance Biotherapeutics

Investors in Iovance Biotherapeutics, Inc.: A Class Action Alert

In recent developments, The Gross Law Firm has issued an urgent notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), particularly for those who suffered financial losses during a specified class period. Investors are strongly encouraged to engage with the firm regarding potential claims as a class action lawsuit progresses.

Overview of the Class Action

According to The Gross Law Firm, investors who bought IOVA shares between May 9, 2024, and May 8, 2025, may qualify for participation in this class action. The firm seeks to appoint a lead plaintiff, an individual who can represent the interests of all affected parties. However, it is important to note that being appointed to this leading role is not a prerequisite for anyone wishing to recover losses sustained during the class period.

Allegations of Misconduct

The allegations brought forth in the class action highlight that Iovance's executives made overly optimistic statements to investors while simultaneously concealing key negative information about the company’s financial health and market potential. Namely, the complaint asserts that Iovance was not adequately prepared to meet the market demands for its therapies or to optimize its existing treatment center network.

A significant turning point occurred on July 25, 2024, when Iovance disclosed its second-quarter fiscal results for 2024, which included a downward revision of its revenue projections. The firm cited various issues impacting performance: annual maintenance on its iCTC facility resulted in dramatically reduced capacity, disappointing sales of Proleukin, and inconsistencies in treatment initiation rates by associated treatment centers. In the aftermath of this news, investor confidence plummeted, resulting in Iovance shares dwindling from a closing price of $3.17 on May 8, 2025, to a low of $1.75 the following day, marking a drastic decline of nearly 45% within 24 hours.

Important Deadline for Shareholders

Shareholders need to act promptly, as the deadline to register for this class action is July 14, 2025. Those who wish to safeguard their rights and possibly recover losses should ensure their registration is completed ahead of this date. Investors can register their information through the dedicated form provided by The Gross Law Firm.

Next Steps for Affected Investors

Once registered, shareholders will gain access to a portfolio monitoring tool designed to keep them informed on the status of the case as it progresses. This service is offered at no cost or obligation, demonstrating the firm's commitment to protecting investors’ interests.

Why The Gross Law Firm?

The Gross Law Firm boasts a strong track record in handling class action lawsuits and is committed to advocating for investors who have suffered due to fraudulent actions or misleading practices by companies. Their mission includes promoting corporate responsibility and ensuring that shareholders are awarded justly for their losses. This class action is a vital opportunity for Iovance investors to seek recovery for their financial suffering amidst claims of corporate misrepresentation.

For further assistance or to learn more about how to participate, investors can reach out directly to The Gross Law Firm by contacting them through the provided contact channels.

Contact Information

• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

The situation serves as a crucial reminder for investors to remain vigilant about corporate disclosures and to ensure they are informed of their rights when financial losses occur due to potentially negligent business practices.